Cancer Treatment Research
CFDA 93.395 · Federal Grants & Funding
Total Funding
$8.76B
Awards
4K
Recipients
632
States
51
Last Updated
Mar 20, 2026
Yearly Funding Trend
| Fiscal Year | Obligations | Awards | YoY Change |
|---|---|---|---|
| 2024 | $7.62B | 3K | |
| 2025 | $985.3M | 784 | -87.1% |
| 2026 | $151.2M | 90 | -84.7% |
Award Type Mix
| Type | Obligations | Awards |
|---|---|---|
| $0 | 0 |
Top 50 Awards under CFDA 93.395
Largest individual obligations for Cancer Treatment Research.
| Award | Recipient | Awarding Agency | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_U10CA180886_075 COG NCTN YEAR 12 BIQSFP PROGRESS REPORT - PROJECT SUMMARY SINCE THE INTRODUCTION OF CHEMOTHERAPY FOR THE TREATMENT OF CHILDHOOD LEUKEMIA MORE THAN 60 YEARS AGO, THE PROGNOSIS OF C… | PUBLIC HEALTH INSTITUTE California | Department of Health and Human Services National Institutes of Health | MONROVIA, CA-31 | 2024 | $333,720,995 |
ASST_NON_UM1CA121947_075 CONSORTIUM FOR ADVANCING MANAGEMENT AND PREVENTION OF CANCER IN PEOPLE WITH HIV - THE MISSION OF THE AIDS MALIGNANCY CONSORTIUM (AMC) IS TO INVESTIGATE THROUGH CLINICAL TRIALS NEW… | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-13 | 2024 | $226,323,195 |
ASST_NON_U10CA180868_075 NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER - NRG OVERALL COMPONENT ABSTRACT NRG ONCOLOGY (NRG) HAS MADE SIGNIFICANT PROGRESS TOWARD ITS GOAL OF IMPROVING THE LIVES OF ADULTS WIT… | NRG ONCOLOGY FOUNDATION INC Pennsylvania | Department of Health and Human Services National Institutes of Health | PA-90 | 2024 | $180,463,644 |
ASST_NON_U10CA180821_075 ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY OPERATIONS CENTER - GY11 BIQSFP FUNDED EXTENSION - PROJECT SUMMARY THE ALLIANCE IS AN EXPERIENCED MULTI-INSTITUTIONAL CANCER CLINICAL TRIA… | BRIGHAM & WOMENS HOSPITAL INC Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2024 | $157,117,425 |
ASST_NON_U10CA180822_075 NRG ONCOLOGY - STATISTICAL AND DATA MANAGEMENT CENTER - ABSTRACT THE MISSION OF THE NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER (SDMC) IS TO PROVIDE ALL NECESSARY EXPERTIS… | UNIVERSITY OF CHICAGO Illinois | Department of Health and Human Services National Institutes of Health | CHICAGO, IL-01 | 2024 | $124,513,663 |
ASST_NON_U10CA180899_075 CHILDREN'S ONCOLOGY GROUP - PROJECT SUMMARY SINCE THE INTRODUCTION OF COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CHILDHOOD LEUKEMIA MORE THAN 60 YEARS AGO, THE PROGNOSIS OF CHI… | UNIVERSITY OF SOUTHERN CALIFORNIA California | Department of Health and Human Services National Institutes of Health | LOS ANGELES, CA-37 | 2024 | $110,600,870 |
ASST_NON_U10CA180819_075 SWOG STATISTICS & DATA MANAGEMENT CENTER COMPLEX - EXTENSION SUPPLEMENT FOR GY06 - PROJECT SUMMARY/ABSTRACT OVERALL COMPONENT THE SWOG STATISTICS AND DATA MANAGEMENT CENTER (SDMC)… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2024 | $96,205,648 |
ASST_NON_U10CA180882_075 ALLIANCE STATISTICS AND DATA MANAGEMENT CENTER - PROJECT SUMMARY THE ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY (ALLIANCE) WAS FOUNDED ON JULY 15, 2011, THROUGH THE MERGER OF 3 LEGA… | MAYO CLINIC Minnesota | Department of Health and Human Services National Institutes of Health | ROCHESTER, MN-01 | 2024 | $95,540,927 |
ASST_NON_U10CA180794_075 ECOG-ACRIN NETWORK GROUP STATISTICS AND DATA MANAGEMENT CENTER - THIS GRANT WILL PROVIDE SUPPORT FOR THE STATISTICS AND DATA MANAGEMENT CENTER (SDMC) OF THE ECOG- ACRIN CANCER RES… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $92,836,256 |
ASST_NON_U24CA055727_075 MACH-LETSGO: MACHINE-LEARNING OF TREATMENT, SURVEY, AND GENETICS TOWARDS OBTAINING CORRECT CLASSIFICATION OF CHRONIC CONDITIONS IN ADULT SURVIVORS IN THE CHILDHOOD CANCER SURVIVOR… | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC Tennessee | Department of Health and Human Services National Institutes of Health | MEMPHIS, TN-09 | 2024 | $81,041,082 |
ASST_NON_U24CA076518_075 A DATA RESOURCE FOR BLOOD AND MARROW TRANSPLANTS AND ADOPTIVE CELLULAR THERAPY RESEARCH - PROJECT SUMMARY/ABSTRACT THE CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARC… | THE MEDICAL COLLEGE OF WISCONSIN, INC. Wisconsin | Department of Health and Human Services National Institutes of Health | MILWAUKEE, WI-04 | 2024 | $76,350,010 |
ASST_NON_P01CA018029_075 ADULT LEUKEMIA RESEARCH CENTER - PROJECT SUMMARY/ABSTRACT OVERALL ACUTE MYELOID LEUKEMIA (AML) AND MULTIPLE MYELOMA (MM) ARE DISEASES OF THE ELDERLY, WITH MEDIAN INCIDENCE OF DISE… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | WA-90 | 2024 | $69,669,587 |
ASST_NON_P01CA108671_075 MYELOPROLIFERATIVE NEOPLASMS-RESEARCH CONSORTIUM - OVERALL ABSTRACT MYELOPROLIFERATIVE NEOPLASM- RESEARCH CONSORTIUM P.I. RONALD HOFFMAN M.D. THE MYELOPROLIFERATIVE NEOPLASM RESEA… | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-13 | 2024 | $64,151,425 |
ASST_NON_UM1CA181255_075 AIDS AND CANCER SPECIMEN RESOURCE (ACSR) - ABSTRACT THE AIDS EPIDEMIC, INITIALLY RECOGNIZED IN THE EARLY 1980'S, CURRENTLY AFFECTS MORE THAN 35 MILLION PEOPLE WORLDWIDE. INFECTION… | GEORGE WASHINGTON UNIVERSITY (THE) District of Columbia | Department of Health and Human Services National Institutes of Health | DC-98 | 2024 | $55,771,666 |
ASST_NON_U24CA196173_075 COG BIOSPECIMEN BANK TO SUPPORT NCI NCTN (U24) - PROJECT SUMMARY THE CHILDREN’S ONCOLOGY GROUP (COG) IS THE PEDIATRIC CLINICAL TRIALS GROUP OF THE NATIONAL CLINICAL TRIALS NETWORK… | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL Ohio | Department of Health and Human Services National Institutes of Health | COLUMBUS, OH-03 | 2024 | $54,100,946 |
ASST_NON_U01AI069911_075 EAST AFRICA INTERNATIONAL EPIDEMIOLOGY DATABASE TO EVALUATE AIDS (IEDEA) REGIONAL CONSORTIUM - PROJECT SUMMARY/ABSTRACT: OUR PRIMARY GOAL CONTINUES TO BE THE PROVISION OF ANSWERS… | TRUSTEES OF INDIANA UNIVERSITY Indiana | Department of Health and Human Services National Institutes of Health | INDIANAPOLIS, IN-07 | 2024 | $52,173,936 |
ASST_NON_P01CA049605_075 BONE MARROW GRAFTING AND CELLULAR THERAPY FOR LEUKEMIA AND LYMPHOMA - OVERALL PROGRAM PROJECT GRANT: PROJECT SUMMARY/ABSTRACT HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS AN EFFECT… | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Health and Human Services National Institutes of Health | STANFORD, CA-16 | 2025 | $44,009,007 |
ASST_NON_P01CA023766_075 IMMUNOBIOLOGY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - ABSTRACT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) IS AN ESTABLISHED THERAPY WITH CURATIVE INTENT F… | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH New York | Department of Health and Human Services National Institutes of Health | NY-90 | 2024 | $39,987,910 |
ASST_NON_UM1CA081457_075 PEDIATRIC BRAIN TUMOR CONSORTIUM A MULTI-INSTITUTIONAL CONSORTIUM DEVOTED TO NOVEL PHASE I AND II CLINICAL EVALUATIONS OF EXPERIMENTAL TREATMENT APPROACHES FOR PEDIATRIC CNS TUMOR… | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC Tennessee | Department of Health and Human Services National Institutes of Health | MEMPHIS, TN-09 | 2024 | $39,949,612 |
ASST_NON_P01CA114046_075 TARGETED THERAPIES IN MELANOMA - PROJECT SUMMARY - OVERALL THE CLINICAL LANDSCAPE OF MELANOMA IS EVOLVING RAPIDLY, HOWEVER, A SIGNIFICANT FRACTION OF INDIVIDUALS… | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY Pennsylvania | Department of Health and Human Services National Institutes of Health | PA-90 | 2026 | $37,068,087 |
ASST_NON_P01CA066996_075 DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES IN HUMAN LEUKEMIAS - OVERALL PROGRAM SUMMARY THE OVERALL GOAL OF THIS PROGRAM IS TO IMPROVE OUTCOMES IN THE TREATMENT OF HUMAN LEUKEMIA… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2024 | $34,802,376 |
ASST_NON_U10CA180863_075 CANADIAN CANCER TRIALS GROUP - CANADIAN COLLABORATING CLINICAL TRIALS NETWORK - CANADIAN CANCER TRIALS GROUP PI = DANCEY, JANET US NATIONAL CLINICAL TRIALS NETWORK – CANADIAN COLL… | QUEENS UNIVERSITY AT KINGSTON | Department of Health and Human Services National Institutes of Health | — | 2024 | $34,570,409 |
ASST_NON_UM1CA228823_075 CHILDREN'S ONCOLOGY GROUP PEDIATRIC EARLYPHASE CLINICAL TRIAL NETWORK - PROJECT SUMMARY/ABSTRACT THE MISSION OF THE PEDIATRIC EARLY PHASE CLINICAL TRIALS NETWORK (PEP-CTN) IS TO I… | PUBLIC HEALTH INSTITUTE California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $32,298,584 |
ASST_NON_P01CA111412_075 NK CELLS, THEIR RECEPTORS AND CANCER THERAPY - RECENT HIGH-PROFILE ADVANCES HAVE REINVIGORATED ENTHUSIASM FOR IMMUNOLOGIC AND CELL-BASED THERAPIES FOR CANCER. WHILE THE FIRST 15 Y… | REGENTS OF THE UNIVERSITY OF MINNESOTA Minnesota | Department of Health and Human Services National Institutes of Health | MINNEAPOLIS, MN-05 | 2024 | $32,024,266 |
ASST_NON_P01CA078902_075 PREVENTING RELAPSE AFTER NON-MYELOABLATIVE STEM CELL TRANSPLANTATION: THE FINAL CHALLENGE - PROJECT SUMMARY / ABSTRACT - OVERALL THE OVERALL GOAL OF THIS PROGRAM PROJECT GRANT IS… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2024 | $31,545,191 |
ASST_NON_P01CA039542_075 CELLULAR AND MOLECULAR STUDIES OF BONE MARROW TRANSPLANT - OVERALL ABSTRACT GRAFT-VERSUS-HOST DISEASE (GVHD) REMAINS A MAJOR CAUSE OF MORBIDITY AND MORTALITY AFTER ALLOGENEIC HEMA… | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-13 | 2024 | $31,228,587 |
ASST_NON_P01CA065493_075 OFF-THE-SHELF IMMUNE EFFECTOR CELLS FOR HEMATOLOGICAL MALIGNANCIES - PROJECT SUMMARY/ABSTRACT IMMUNE EFFECTOR CELLS (IECS) TARGETING TUMOR ASSOCIATED ANTIGENS, SUCH AS WITH CHIMER… | REGENTS OF THE UNIVERSITY OF MINNESOTA Minnesota | Department of Health and Human Services National Institutes of Health | MINNEAPOLIS, MN-05 | 2024 | $30,630,550 |
ASST_NON_P01CA155258_075 INTEGRATIVE ONCOGENOMICS OF MULTIPLE MYELOMA - PROJECT SUMMARY – OVERALL PROGRAM DANA-FARBER CANCER INSTITUTE THIS RENEWAL APPLICATION STEMS FROM OUR SUCCESSFUL RENEWAL OF OUR PRO… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $27,680,811 |
ASST_NON_P01CA129243_075 TARGETS FOR THERAPY FOR CARCINOMAS OF THE LUNG - PROJECT SUMMARY/ABSTRACT SINCE BIOLOGIC EVENTS UNDERLIE CLINICAL OUTCOMES, WE HYPOTHESIZE THAT UNRAVELING MECHANISMS OF INTRACELLU… | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH New York | Department of Health and Human Services National Institutes of Health | NY-90 | 2025 | $24,498,405 |
ASST_NON_P01CA148600_075 NOVEL CORD BLOOD-DERIVED CELLULAR THERAPIES - OVERALL PROGRAM SUMMARY UMBILICAL CORD BLOOD (CB) IS A VALUABLE SOURCE OF HEMATOPOIETIC PROGENITOR CELLS (HPCS) FOR THE TREATMENT OF… | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER Texas | Department of Health and Human Services National Institutes of Health | TX-90 | 2024 | $24,289,526 |
ASST_NON_UM1CA186709_075 DANA-FARBER/HARVARD CANCER CENTER EXPERIMENTAL THERAPEUTICS CLINICAL TRIALS NETWORK SITE (DF/HCC ETCTN SITE) - THE NCI-DESIGNATED DANA-FARBER/HARVARD CANCER CENTER (DF/HCC) INCLUD… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $23,631,028 |
ASST_NON_P01CA163205_075 CIRCUMVENTING BARRIERS TO EFFECTIVE ONCOLYTIC VIROTHERAPY OF MALIGNANT GLIOMAS - OVERALL PROJECT SUMMARY GLIOBLASTOMA (GBM) AND RECURRENT GBM (RGBM) IS ARGUABLY ONE OF THE MOST FA… | BRIGHAM & WOMENS HOSPITAL INC Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $22,655,025 |
ASST_NON_P01CA125066_075 DISCOVERY OF ANTICANCER AGENTS OF DIVERSE NATURAL ORIGIN - OVERALL PROJECT SUMMARY IN THIS PROGRAM PROJECT RENEWAL APPLICATION, THE APPLICANT GROUP IS REPRESENTATIVE OF THREE PRIM… | OHIO STATE UNIVERSITY, THE Ohio | Department of Health and Human Services National Institutes of Health | COLUMBUS, OH-03 | 2024 | $22,617,917 |
ASST_NON_P01CA055791_075 PDT OPTIMIZATION AND MECHANISMS - DESCRIPTION (PROVIDED BY APPLICANT): HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IS THE 6TH MOST COMMON CANCER WORLDWIDE AND THE 8TH MOST COMM… | HEALTH RESEARCH, INC. New York | Department of Health and Human Services National Institutes of Health | BUFFALO, NY-26 | 2024 | $22,384,526 |
ASST_NON_P01CA214278_075 ENHANCING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES FOR HEMATOLOGICMALIGNANCIES: BEYOND CART 19 - OVERALL PROJECT SUMMARY / ABSTRACT THE LONG-TERM GOALS OF THIS RENEWAL P01 ARE T… | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE Pennsylvania | Department of Health and Human Services National Institutes of Health | PHILADELPHIA, PA-03 | 2024 | $21,306,463 |
ASST_NON_P01CA097132_075 SPHINGOLIPIDS IN CANCER BIOLOGY AND THERAPY - THE OVERALL ORGANIZING HYPOTHESIS OF THIS PROGRAM POSITS THAT BIOACTIVE SPHINGOLIPIDS FUNCTION AS IMPORTANT REGULATORS OF SEVERAL KEY… | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK New York | Department of Health and Human Services National Institutes of Health | NY-90 | 2025 | $21,066,870 |
ASST_NON_UM1CA154967_075 CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER - PROJECT SUMMARY THE CANCER IMMUNOTHERAPY TRIALS NETWORK (CITN) CAME ABOUT FROM DISCUSSIONS AT THE 2… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | WA-90 | 2025 | $20,745,202 |
ASST_NON_UM1CA186689_075 VICKTORY EARLY CLINICAL TRIALS CONSORTIUM - THE NEW ERA IN CANCER DRUG DEVELOPMENT REPRESENTS A PARADIGM SHIFT IN HOW EARLY PHASE STUDIES ARE CONDUCTED RELATIVE TO THE “CONVENTION… | YALE UNIV Connecticut | Department of Health and Human Services National Institutes of Health | NEW HAVEN, CT-03 | 2024 | $20,169,612 |
ASST_NON_UM1CA186691_075 THE JOHNS HOPKINS TRANSLATIONAL SCIENCE TEAM AND CONSORTIUM FOR ETCTN STUDIES - WITH THE EVOLUTION OF THE EXPERIMENTAL THERAPEUTICS CLINICAL TRIALS NETWORK (ETCTN), THE JOHNS HOPK… | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | BALTIMORE, MD-07 | 2024 | $20,058,272 |
ASST_NON_P01CA171983_075 TARGETED SPHINGOLIPID METABOLISM FOR TREATMENT OF AML - PROJECT SUMMARY THROUGH THREE INTER-RELATED AND INTER-DEPENDENT PROJECTS AND FOUR ESSENTIAL CORES, OUR TEAM WILL CONTINUE T… | RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA Virginia | Department of Health and Human Services National Institutes of Health | VA-90 | 2024 | $19,887,649 |
ASST_NON_P01CA163222_075 TARGETABLE EPIGENETIC AND TRANSCRIPTIONAL MECHANISMS IN MELANOMA THATSHAPE THE MICROENVIRONMENT - OVERALL SUMMARY TUMOR-MICROENVIRONMENT INTERACTIONS UNDERLIE FUNDAMENTAL FEATURES… | THE GENERAL HOSPITAL CORPORATION Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2024 | $19,859,146 |
ASST_NON_UM1CA186688_075 TEXAS EXPERIMENTAL CANCER THERAPEUTICS NETWORK - TEX CTN - PROJECT SUMMARY THE TEXAS EXPERIMENTAL CANCER THERAPEUTIC NETWORK (TEX-CTN) IS COMPRISED OF THE UNIVERSITY OF TEXAS MD… | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER Texas | Department of Health and Human Services National Institutes of Health | HOUSTON, TX-09 | 2024 | $18,916,469 |
ASST_NON_P01CA084203_075 PHOTODYNAMIC PRIMING OF CANCER AND IMAGE-GUIDANCE FOR OPTIMAL IMMUNE RESPONSE - OVERALL PROGRAM SUMMARY FOR OPTIMAL CANCER THERAPY, COMBINATION APPROACHES THAT ARE MECHANISTICALLY… | THE GENERAL HOSPITAL CORPORATION Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-08 | 2024 | $18,846,157 |
ASST_NON_UM1CA186717_075 PHASE 1 AND 2 MOLECULAR AND CLINICAL PHARMACODYNAMIC TRIALS ETCTN - PROJECT SUMMARY AS THE CALIFORNIA CANCER CONSORTIUM (CCC), FOUR NATIONAL CANCER INSTITUTE (NCI)-DESIGNATED CANC… | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE California | Department of Health and Human Services National Institutes of Health | DUARTE, CA-31 | 2024 | $17,918,626 |
ASST_NON_UM1CA186712_075 THE OHIO STATE UNIVERSITY AS A LEAD ACADEMIC ORGANIZATION (LAO) FOR THE EXPERIMENTAL THERAPEUTICS CLINICAL TRIALS NETWORK - PROJECT SUMMARY THIS PROJECT ENCOMPASSES A MULTI-DISCIP… | OHIO STATE UNIVERSITY, THE Ohio | Department of Health and Human Services National Institutes of Health | COLUMBUS, OH-03 | 2024 | $17,645,583 |
ASST_NON_P01CA206978_075 COMPREHENSIVE DISSECTION OF THE CLL GENOME & PHENOME TO IMPROVE PATIENT OUTCOMES - OVERALL ABSTRACT ALTHOUGH WE HAVE MADE GREAT STRIDES IN OUR UNDERSTANDING OF THE BIOLOGY AND TRE… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $16,967,366 |
ASST_NON_P01CA225517_075 IMMUNOBIOLOGY AND IMMUNE THERAPYFOR MERKEL CELL CARCINOMA - OVERALL SUMMARY: IMMUNOBIOLOGY AND IMMUNE THERAPY FOR MERKEL CELL CARCINOMA OUR SEATTLE-BASED MCC TEAM, TOGETHER WITH C… | UNIVERSITY OF WASHINGTON Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2025 | $16,967,057 |
ASST_NON_P01CA217959_075 DISCOVERING AND EXPLOITING MECHANISMS OF NEUROBLASTOMA THERAPY RESISTANCE - OVERALL SUMMARY/ABSTRACT THIS IS A REVISED COMPETITIVE RENEWAL APPLICATION FOR A PROGRAM FOCUSED ON HIG… | THE CHILDREN'S HOSPITAL OF PHILADELPHIA Pennsylvania | Department of Health and Human Services National Institutes of Health | PA-90 | 2024 | $15,842,717 |
ASST_NON_UM1CA186644_075 NORTH AMERICAN STAR CONSORTIUM - THIS UM1 RENEWAL APPLICATION IS DESIGNATED THE NORTH AMERICAN STAR CONSORTIUM (NASC), WHICH INCLUDES MOFFITT CANCER CENTER (MCC) AS THE LEAD ACAD… | UNIVERSITY HEALTH NETWORK | Department of Health and Human Services National Institutes of Health | — | 2024 | $14,859,350 |
ASST_NON_P01CA236749_075 UNDERSTANDING AND OVERCOMING T CELL IMMUNOSUPPRESSION IN GLIOBLASTOMA - ABSTRACT GLIOBLASTOMA (GBM) REMAINS A FORMIDABLE CANCER TO TREAT WITH ONLY ANECDOTAL EXAMPLES OF LONG-TERM… | BRIGHAM & WOMENS HOSPITAL INC Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $14,151,159 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Spending by State
| State | Funding | Awards |
|---|---|---|
| California | $1.35B | 456 |
| New York | $1.06B | 349 |
| Massachusetts | $1.01B | 272 |
| Pennsylvania | $645.3M | 226 |
| Texas | $619.2M | 356 |
| Washington | $465.2M | 107 |
| Ohio | $324.0M | 145 |
| Illinois | $313.9M | 112 |
| Minnesota | $300.5M | 92 |
| North Carolina | $254.8M | 152 |
| Maryland | $233.3M | 109 |
| Tennessee | $218.4M | 54 |
| Florida | $190.0M | 127 |
| Michigan | $171.7M | 103 |
| Wisconsin | $163.7M | 46 |
| Connecticut | $136.3M | 58 |
| Indiana | $135.6M | 52 |
| Missouri | $128.7M | 72 |
| Georgia | $128.4M | 91 |
| Virginia | $115.5M | 69 |
| District of Columbia | $91.2M | 28 |
| Colorado | $67.7M | 52 |
| Kentucky | $51.3M | 33 |
| New Jersey | $48.8M | 39 |
| Nebraska | $47.5M | 33 |
| South Carolina | $46.8M | 32 |
| Oregon | $46.0M | 34 |
| Alabama | $41.7M | 37 |
| Arizona | $38.9M | 28 |
| Oklahoma | $37.8M | 20 |
| Iowa | $27.3M | 15 |
| Arkansas | $24.1M | 11 |
| Utah | $23.0M | 18 |
| New Mexico | $22.2M | 13 |
| New Hampshire | $21.3M | 14 |
| Louisiana | $14.7M | 15 |
| Rhode Island | $12.4M | 11 |
| Maine | $11.6M | 5 |
| Kansas | $11.2M | 12 |
| West Virginia | $8.0M | 6 |
| Hawaii | $7.0M | 5 |
| Vermont | $6.9M | 3 |
| Delaware | $3.2M | 3 |
| Nevada | $2.7M | 2 |
| Montana | $2.4M | 1 |
| Alaska | $937K | 1 |
| South Dakota | $699K | 3 |
| Idaho | $395K | 1 |
| Puerto Rico | $370K | 1 |
| Wyoming | $345K | 1 |
| North Dakota | $317K | 1 |
Top Recipients
Agencies Administering This Program
Source: USAspending.gov · All Programs